Literature DB >> 14746823

National survey of apheresis activity in Italy (2000).

Giustina De Silvestro1, Piero Marson, Gaspare Elios Russo, Maria Vicarioto, Carla Donadel.   

Abstract

Data collection on apheresis in Italy throughout 2000, including techniques, machines, clinical indications and adverse effects, has been performed by means of a standardized questionnaire. These data provided from 102 Apheresis Units from 19 Italian regions, albeit rough, are sufficiently informative. In 2000 a total number of 164,943 apheresis procedures has been carried out, with a clear-cut prevalence of productive apheresis (90.8%), that has been performed by all Apheresis Units. Lombardy, Venetia and Liguria have been the most active regions for therapeutic apheresis (54.0% of the total activity). Adverse events, predominantly mild ones (i.e., paresthesia due to citrate-induced hypocalcemia) have occurred in 0.59% of productive and in 6.75% of therapeutic apheresis sessions, particularly in the course of peripheral blood stem cell collection (13.0%).

Entities:  

Mesh:

Year:  2004        PMID: 14746823     DOI: 10.1016/j.transci.2003.05.003

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  3 in total

1.  A Retrospective Analysis of Apheresis Donor Deferral and Adverse Reactions at a Tertiary Care Centre in India.

Authors:  Disha Arora; Ketan Garg; Ankit Kaushik; Richa Sharma; D S Rawat; A K Mandal
Journal:  J Clin Diagn Res       Date:  2016-11-01

2.  Therapeutic plasma exchange using the Spectra Optia cell separator compared with the COBE Spectra.

Authors:  Do Kyun Kim; Sinyoung Kim; Seok Hoon Jeong; Hyun Ok Kim; Hyung Jik Kim
Journal:  Ann Lab Med       Date:  2015-09       Impact factor: 3.464

3.  Plasmapheresis Is Associated With Better Renal Outcomes in Lupus Nephritis Patients With Thrombotic Microangiopathy: A Case Series Study.

Authors:  Qiu-Yu Li; Feng Yu; Fu-De Zhou; Ming-Hui Zhao
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.